Abstracts tagged "autoimmune diseases"

Abstract Number: 0935 • ACR Convergence 2022
Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the…
Abstract Number: 1142 • ACR Convergence 2022
The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
Rheyanna Clemens¹, Tyson Dawson¹, Katherine Owen², Amrie Grammer³ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Previous genetic association studies identified a 9 gene region of Xq28 containing IRAK1 as a risk locus for SLE. IRAK1 plays key roles downstream…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1629 • ACR Convergence 2022
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada
Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…
Abstract Number: 1836 • ACR Convergence 2022
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
Faria Sami¹, Dennis Kumi¹, Sumbul Liaqat² and Hania Sami³, ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Shalamar Medical and Dental College, Chicago, IL
Background/Purpose: It has been hypothesized that autoimmunity may play a role in the pathophysiology of schizophrenia (SCZ). Several autoimmune disorders (AID) have also been noted…
Abstract Number: 2182 • ACR Convergence 2022
mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis
Xiaowei Zhang¹, Antony Jozic¹, Pingfang Song¹, Qiang Xu², Xiaofei Shi³, Hong Wang⁴, Lindsey Bishop¹, Hillary Struthers¹, John Rutledge⁵, Shuang Chen¹, Fei Xu¹, Meaghan Hancock¹, Daocheng Zhu⁶, Gaurav Sahay¹ and Cong-Qiu Chu¹, ¹Oregon Health & Science University, Portland, OR, ²Guangzhou University of Chinese Medicine, Guangzhou, China, ³Henan University of Science and Technology, Luoyang, China, ⁴Wenzhou Medical University, Wenzhou, China, ⁵Portland VA Research Foundation, Portland, ⁶Shanghai Kexin Biotechnology, Shanghai, China
Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: 0009 • ACR Convergence 2022
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
Xiaodong Wang, Mark Matijevic, Allen Poma, Shauna Quinn, Minggeng Gao, Lisa Crockett, Jessica Karnes, Keith Wilcoxen and Hua Mu, Zenas BioPharma, Waltham
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…
Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Lara Sánchez-Bilbao¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa⁹, Paloma Vela-Casampere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesús Carlos Fernández-López¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Julio Sánchez-Martín¹, Mónica Calderón-Goercke¹, José Luis Hernández¹, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…
Abstract Number: 0378 • ACR Convergence 2022
Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics
Atul Deodhar¹, Sonam Kiwalkar², Kim Phung Nguyen³, Rose Quinn³, David Perham⁴, William Malatestinic⁵, Rebecca Bolce⁶, Theresa Hunter⁵, Pragya Khurana⁷ and Shireesh Bhalerao⁴, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Washington State University, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Private Practice, Portland, OR, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Cincinnati, OH, ⁷ICON plc, Blue Bell, PA
Background/Purpose: Patients with chronic back pain (CBP; back, buttock, or hip pain ≥ 3 months) where the underlying cause may be axSpA are usually first…
Abstract Number: 0637 • ACR Convergence 2022
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Carolina Munoz¹, Sindu Johnson², Zahi Touma¹, Zareen Ahmad², Dennisse Bonilla¹, Linda Hiraki³, Arthur Bookman² and Joan Wither⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently the immune changes that lead to the transition from asymptomatic Anti-Nuclear Antibody (ANA) positivity to symptomatic disease are unknown. Studies in our laboratory…
Abstract Number: 0721 • ACR Convergence 2022
Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
Ashley Archer¹, Ruth Topless², Angelo Gaffo¹, Nicola Dalbeth³, Lisa Stamp⁴, Philip Robinson⁵ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵School of Clinical Medicine, University of Queensland, Brisbane, Australia
Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
Abstract Number: 0942 • ACR Convergence 2022
Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls
Alexandra Theisen¹, Kathleen Lane¹, Jodi Skiles¹, Amanda Saraf¹, Stacey Tarvin², Tamara Hannon¹, Marcia Shew¹ and Melissa Oliver¹, ¹Indiana University School of Medicine, Indianapolis, IN, ²Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Medical evidence suggests decreased ovarian reserve in women with rheumatic disease; however, studies in adolescents are lacking. Anti-Mullerian hormone (AMH) levels in serum are…
Abstract Number: 1161 • ACR Convergence 2022
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
Marie-Christin Hoffmann¹, Natalie Fadle¹, Evi Regitz¹, Klaus-Dieter Preuss¹, Marina Zaks², Elisabeth Stöger³, Vincent Zimmer⁴, Philipp Klemm⁵, Gunter Assmann⁶, Bernhard Thurner⁷, Claudia Pföhler⁸, Joerg Thomas Bittenbring¹, Christoph Kessel⁹ and Lorenz Thurner¹, ¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, ²Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, ³Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, ⁴Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, ⁵Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ⁶Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, ⁷Department of Pediatrics, Klinikum Kempten, Kempten, Germany, ⁸Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, ⁹Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany
Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].